This page contains a Flash digital edition of a book.
Contents


Supplement Contents


Introduction 03 Non-biological complex drugs: an introduction Jacques Rottembourg


Key issues 11 NBCDs and follow-on products: the key issues Christine Clark


Characterisation 07 Characterisation of non-biological complex drugs Julia Schnorr and Peter Langguth


Focus 13 Glatiramoids and follow-on compounds Jana Lizrova Preiningerova


17 NBCDs and multiple sclerosis Emanuel D’Amico and Francesco Patti


Editor, Secondary Care Andrea Porter


Commissioning Editor Annabel De Coster


Art/Design Sarah Everett


Sales Manager, Secondary Care Jennifer Richardson


Managing Director Alex Beaumont


Copyright © Cogora Limited 2016. The contents of this publication are protected by copyright. All rights reserved. No part of this publication may be produced, stored in a retrieval system or transmitted in any form or by any means without the written permission of the publisher. The views expressed in this publication are not necessarily those of the publisher or editorial advisors. While the publisher and editorial advisors have taken every care with regard to accuracy of editorial and advertisement contributions, they cannot be held responsible for any errors or omissions contained therein. Published in the United Kingdom by Cogora Limited, 140, London Wall, London EC2Y 5DN, UK


T +44 (0)20 7214 0500 E hpe@cogora.com


F +44 (0)20 7214 0501 W www.cogora.com


The articles have been written independently by the respective authors, and Teva has completed a review for medical and factual accuracy only


1 www.hospitalpharmacyeurope.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24